A new paper from Peter Schafer, et al, of Celgene shows how biomarkers can be used to monitor treatment response in an inflammatory disease setting. The early timepoints show a dose-dependent biomarker response while the later timepoints show a more normalized response, possibly correlated with reduced disease severity.

Read Paper »